Please login to the form below
hyperkalaemia
This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.
NICE says no to AZ and Vifor’s rival hyperkalaemia drugs
Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as
Latest news
-
AZ gets US approval for Veltassa rival Lokelma
But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... AstraZeneca has picked up FDA approval for its hyperkalaemia treatment Lokelma, allowing it to compete head-to-head with rival Vifor Pharma on both sides of
-
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval
The company has a number of promising new cancer treatments, and has just received FDA approval for the delayed hyperkalaemia drug Lokelma.
-
AZ finally gets EU nod for Veltassa rival Lokelma
And expects a US FDA verdict for the hyperkalaemia treatment later this year. ... The approval of Lokelma “addresses a significant unmet need by bringing a rapid and sustained therapeutic option for patients with hyperkalaemia,” she added.
-
Vifor wins European approval for Veltassa
European Commission approves the drug to treat hyperkalaemia. The European Commission (EC) has approved Vifor’s Veltassa (patiromer) to treat adults with hyperkalaemia, a potentially life threatening condition which can cause ... The European
-
FDA turns down AZ's ZS-9 once again on manufacturing issues
The US regulator issued a Complete Response Letter to ZS Pharma regarding its application for ZS-9 (sodium zirconium cyclosilicate) as a treatment for the condition - known as hyperkalaemia - after an ... Veltassa was launched in early 2016 - becoming
AZ gets US approval for Veltassa rival Lokelma
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval
AZ finally gets EU nod for Veltassa rival Lokelma
Vifor wins European approval for Veltassa
More from news
Approximately 5 fully matching, plus 8 partially matching documents found.
Latest Intelligence
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... For instance, we are exploring patient
-
Deal Watch July 2016
for the treatment of hyperkalaemia.
-
Deal Watch November 2015
Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,
-
Pharma deals during October 2013
Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
Deal Watch July 2016
Pharma deals during October 2013
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Distracted boyfriend: the secret of a successful long-distance relationship
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Vertex gains FDA fast track designation for diabetes stem cell therapy
- Onyx Health Launch Creative Studio After Record Year
- Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader
- Roche appoints Philip Atkinson to new global role
- AZ’s comeback drug cediranib stumbles in phase 3 trial
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
